Your session is about to expire
← Back to Search
Stereotactic Body Radiation Therapy for Prostate Cancer
Phase 1
Waitlist Available
Led By Sagus Sampath
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial studies how to safely use radiation to treat prostate cancer after surgery, aiming to limit damage to healthy tissue.
Who is the study for?
Men who've had prostate cancer surgery can join this trial. They should be in decent physical shape (ECOG 0-2), have no signs of cancer spread based on recent scans, and a PSA level up to 2.0. Men with certain high-risk features from their surgery are also eligible. Those with uncontrolled illnesses, other cancers within the last 5 years (except skin cancer), or taking experimental treatments can't join.
What is being tested?
The trial is testing how safe and effective stereotactic body radiation therapy is for prostate cancer patients post-surgery. It's looking for the best dose that targets the tumor while sparing healthy tissue, alongside assessing quality-of-life and analyzing biomarkers.
What are the potential side effects?
Stereotactic body radiation may cause side effects like fatigue, skin reactions at the treatment site, urinary issues, bowel discomfort, and erectile dysfunction due to its focus on areas affected by prostate cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
MTD, defined as the highest dose tested in which fewer than 33% of patients experienced dose limiting toxicity, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Secondary study objectives
Biochemical progression-free survival
Incidence of acute toxicities observed at each dose level graded according to the NCI CTCAE version 4.0
Incidence of late toxicities observed at each dose level graded according to the NCI CTCAE version 4.0
+1 moreSide effects data
From 2016 Phase 2 trial • 59 Patients • NCT0008743855%
Dyspnea
38%
Fatigue
33%
Cough
24%
Hemoglobin
20%
Pulmonary/upper respiratory - Other
16%
Chest wall pain
16%
Fracture NOS
16%
Forced expiratory volume
15%
Nausea
15%
Chest pain
15%
Pneumonitis NOS
11%
Blood/bone marrow - Other
11%
Dermatitis radiation NOS
11%
Blood creatinine increased
9%
Pleural effusion
9%
Vomiting NOS
9%
Hyperglycemia NOS
9%
Hypoalbuminemia
9%
Lymphopenia
9%
Pulmonary function test NOS decreas
7%
Hypocalcemia
7%
Abdominal pain NOS
7%
Headache
7%
Hypoxia
7%
Edema: limb
7%
Blood bilirubin increased
7%
Peripheral sensory neuropathy
5%
Pyrexia
5%
Atrial fibrillation
5%
Diarrhea NOS
5%
Hypokalemia
5%
Muscle weakness NOS
5%
Rigors
5%
Myalgia
5%
Musculoskeletal/soft tissue - Other
5%
Hyponatremia
5%
Pain - Other
5%
Infection with Grade 3 or 4 neutrop
5%
Activated partial thromboplastin ti
5%
Blood alkaline phosphatase increase
5%
Metabolic/laboratory - Other
5%
Weight decreased
5%
Renal/genitourinary - Other
5%
Atelectasis
4%
Anorexia
2%
Dysphagia
2%
Lymphatics - Other
2%
Pulmonary hypertension NOS
2%
Cardiac general - Other
2%
Constipation
2%
Insomnia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Stereotactic Body Radiation Therapy (SBRT)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (SBRT)Experimental Treatment3 Interventions
Patients receive 5 fractions of SBRT over 1.5 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
stereotactic body radiation therapy
2019
Completed Phase 2
~480
quality-of-life assessment
2012
Completed Phase 3
~2780
Find a Location
Who is running the clinical trial?
City of Hope Medical CenterLead Sponsor
598 Previous Clinical Trials
1,923,350 Total Patients Enrolled
15 Trials studying Prostate Cancer
5,633 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,886 Previous Clinical Trials
41,020,911 Total Patients Enrolled
569 Trials studying Prostate Cancer
529,860 Patients Enrolled for Prostate Cancer
Sagus SampathPrincipal InvestigatorCity of Hope Medical Center
1 Previous Clinical Trials
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Treatment (SBRT)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger